medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2019, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2019; 35 (2)

Glanzmann thrombasthenia: key concepts of the disease

Martínez SLM, Quintero MDA

Language: Spanish
References: 29
Page: 1-12
PDF size: 372.01 Kb.


ABSTRACT

Glanzmann's thrombasthenia (GT) is an autosomal recessive disorder in which there is a severe reduction or absence of platelet aggregation. It is due to the qualitative or quantitative alterations of integrin α IIb or integrin β 3, encoded by the ITGA2B and ITGB3 genes and related to glycoprotein IIb / IIIa, which intervene in platelet activation. The highest incidence of GT has been reported in the Jewish-Iraqi population, but it has also been reported in Israel, Jordan, Saudi Arabia, Italy, and in smaller numbers in Gypsy and Pakistani families. Despite being uncommon, this disorder should be suspected in cases of severe spontaneous or trauma-induced bleeding disorders, ranging from gastrointestinal and mucocutaneous hemorrhages such as epistaxis and recurrent, difficult to manage gingival hemorrhages, which are potentially fatal and more than 75% of cases require blood or platelet transfusion. To confirm the diagnosis, the laboratory findings are characterized by prolonged bleeding times, decreased clot retraction and abnormal platelet aggregation responses to physiological stimuli. Although there is currently no cure for the disease, adequate treatments with platelet transfusions and in case of refractoriness, the use of factor VIIa, allow a good prognosis for patients. There is still much to study in these cases, because of this, new studies are being conducted for the possibility of other treatments, including platelet gene therapy.


REFERENCES

  1. Boilard E, Nigrovic PA. Plaquetas. En: Firestein G, Budd R, Sherine E, McInnes I, James R. Tratado de reumatología. España: Elsevier; 2018.p. 264-73.

  2. Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, et al. Hematology: Basic Principles and Practice. España: Elsevier; 2018. p.1857-69.

  3. Swathi J, Gowrishankar A, Jayakumar SA, Jain K. A rare case of bleeding disorder: Glanzmann's thrombasthenia. Ann Afr Med. 2017;16:196-8.

  4. Barg AA, Hauschener H, Misgav M, Lubetsky A, Levy-Mendelowitz S, Livnat T et al. A novel approach using ancillary tests to guide treatment of Glanzmann thrombasthenia patients undergoing surgical procedures. Blood Cells Mol Dis. 2018 Aug;72:44-48. DOI: 10.1016/j.bcmd.2018.07.003

  5. Reverter JC, Vicente V. Enfermedades de la hemostasia. En: Rozman F. Medicina interna. 18a ed. España: Elsevier; 2016. p. 1691-1719.

  6. Zahran AM, Saad K, Elsayh KI, Albilihed MA, Embaby M. Identification of Clinicopathological Spectrum, Platelet Glycoprotein IIb/IIIa complex and Platelet Antibodies in Egyptian Children with Glanzmann's Thrombasthenia. Arch Immunol Ther Exp (Warsz). 2017 Dec;65(6):565-571. DOI: 10.1007/s00005-017-0454-x.

  7. Ambruso DR, Nuss R, Wang M. Hematologic Disorders. En: Hay WW Jr., Levin MJ, Deterding RR, Abzug MJ. eds. Current Diagnosis & Treatment: Pediatrics, 24th ed. New York: McGraw-Hill; 2018

  8. Rao A, Coller BS. Hereditary Qualitative Platelet Disorders. En: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et al. Williams Hematology. 9e ed. New York: McGraw-Hill; 2016.

  9. Reyes MU, Sandoval TFA, Morales S, Villalpando M, Sandoval D, Reyes U. Trombastenia de Glanzmann y embarazo: reporte de un caso y revisión bibliográfica. Ginecol Obstet Mex.2016;84 (10):674-8.

  10. Borhany M, Fatima H, Naz A, Patel H, Shamsi T. Pattern of bleeding and response to therapy in Glanzmann thrombasthenia. Haemophilia. 2012;18(6):423-25.

  11. Sharma R, Pérez J, Jobe SM. Congenital Disorders of Platelet Function and Number. Pediatr Clin North Am. 2018;65(3):561-78.

  12. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008;112(8):3011-25.DOI: 10.1182/blood-2008-06-077891.

  13. Mitchell WB, Li J, French DL, Coller BS. AlphaIIbbeta3 biogenesis is controlled by engagement of alphaIIb in the calnexin cycle via the N15-linked glycan. Blood.2006;107(7):2713-19.

  14. Mitchell WB, Li J, Murcia M, Valentin N, Newman PJ, Coller BS. Mapping early conformational changes in alphaIIb and beta3 during biogenesis reveals a potential mechanism for alphaIIbbeta3 adopting its bent conformation. Blood. 2007;109:3725-32.

  15. Anderson JA, Thomas AE. Investigating easy bruising in a child. BMJ 2010;341:456. DOI: https://doi.org/10.1136/bmj.c4565

  16. Recht M, Chitlur M, Lam Derek, Sarnaik S, Rapjpurkar M, Cooper DL, et al. Epistaxis as a Common Presenting Symptom of Glanzmann’s Thrombasthenia, a Rare Qualitative Platelet Disorder: Illustrative Case Examples. Case Reports in Emergency Medicine. 2017, 1-6.

  17. Fiore M, Pillois X, Nurden P, Nurden AT, Austerlitz F. Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families. Eur J Hum Genet. 2011;19:981–7. DOI: 10.1038/ejhg.2011.61

  18. Nurden AT, Pillois X, Wilcox DA. Glanzmann Thrombasthenia: State of the Art and Future Directions. Semin Thromb Hemost. 2013 Sep;39(6):642-55. DOI: 10.1055/s-0033-1353393.

  19. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011;118(23):5996-6005. DOI: 10.1182/blood-2011-07-365635

  20. Sebastiano C, Bromberg M, Breen K, Hurford MT. Glanzmann's thrombasthenia: Report of a case and review of the literature. Int J Clin Exp Pathol. 2010 25;3(4):443-7.

  21. Nurden AT, Pillois X, Nurden P. Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment. Expert Rev Hematol. 2012;5(5):487-503. DOI: 10.1586/ehm.12.46.

  22. Leo VC, Morgan NV, Bem D, Jones ML, Lowe GC, Lordkipanidzé M, et al. UK GAPP Study Group. Use of next-generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders. J Thromb Haemost. 2015;13(4):643-50. DOI: 10.1111/jth.12836.

  23. Nurden AT, Pillois X, Fiore M, Alessi MC, Bonduel M, Dreyfus M, et al. Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in Glanzmann Thrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort. Hum Mutat. 2015;36(5):548-61. DOI: 10.1002/humu.22776.

  24. Loroch S, Trabold K, Gambaryan S, Reiß C, Schwierczek K, Fleming I, et al. Alterations of the platelet proteome in type I Glanzmann thrombasthenia caused by different homozygous delG frameshift mutations in ITGA2B. Thromb Haemost. 2017;117(3):556-69. DOI: 10.1160/TH16-07-0515.

  25. Pillois X, Nurden AT. Linkage disequilibrium amongst ITGA2B and ITGB3 gene variants in patients with Glanzmann thrombasthenia confirms that most disease-causing mutations are recent. Br J Haematol. 2016;175(4):686-95.DOI: 10.1111/bjh.14283.

  26. Sandrock-Lang K, Oldenburg J, Wiegering V, Halimeh S, Santoso S, Kurnik K, et al. Characterisation of patients with Glanzmann thrombasthenia and identification of 17 novel mutations. Thromb Haemost. 2015;113(4):782-91. DOI: 10.1160/TH14-05-0479

  27. Maclachlan A, Watson SP, Morgan NV. Inherited platelet disorders: Insight from platelet genomics using next-generation sequencing. Platelets. 2017;28(1):14-9. DOI: 10.1080/09537104.2016.1195492.

  28. Cid AR, Montesinos P, Sánchez-Guiu I, Haya S, Lorenzo JI, Sanz J, et al. Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia. Clin Case Rep. 2017 (11):1887-90. DOI: 10.1002/ccr3.1206.

  29. Ramzi M, Dehghani M, Haghighat S, Nejad HH. Stem Cell Transplant in Severe Glanzmann Thrombasthenia in an Adult Patient. Exp Clin Transplant. 2016 Dec;14(6):688-90. DOI: 10.6002/ect.2014.0165.




2020     |     www.medigraphic.com